Education
About Us
Working with TipRanks
Follow Us
Tango Therapeutics (TNGX)
NASDAQ:TNGX
TNGX Stock Chart & Stats
$12.90
-$0.22(-6.34%)
At close: 4:00 PM EST
$12.90
-$0.22(-6.34%)
Day’s Range― - ―
52-Week Range$1.03 - $13.48
Previous CloseN/A
Volume187.94K
Average Volume (3M)3.04M
Market Cap
$1.74B
Enterprise Value$1.39B
Total Cash (Recent Filing)$152.81M
Total Debt (Recent Filing)$34.76M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Mar 30, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding134,677,100
10 Day Avg. Volume3,795,201
30 Day Avg. Volume3,037,748
Financial Highlights & Ratios
PEG Ratio-0.25
Price to Book (P/B)1.69
Price to Sales (P/S)8.02
P/FCF Ratio-2.55
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue20.91
Enterprise Value/Gross Profit21.29
Enterprise Value/Ebitda-13.37
Forecast
1Y Price Target
$15.67Price Target Upside21.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Precision Oncology PlatformTango’s genetic and computational focus on synthetic lethality targets creates a durable competitive edge by enabling tumor-specific therapies and clearer biomarker-driven patient selection. This platform can generate multiple programs and attract partners, supporting sustained R&D productivity and licensing opportunities.
Strengthened Leadership And GovernanceThe CEO transition plus the founder’s move to Executive Chair preserves strategic continuity while adding new operational leadership. Combined with an added independent director with finance and biopharma experience, this governance upgrade should improve execution of registrational plans and investor communication over the next several quarters.
Improved Near-term Funding RunwayThe sizable registered offering and reported cash balance extend runway into 2028, materially reducing immediate financing pressure. That funding allows Tango to execute pivotal and combination studies, derisk programs toward value inflection points, and avoid urgent capital raises that could disrupt development timelines.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow forces recurring capital raises, creating dilution risk and limiting strategic flexibility. Until products generate sales or large milestone receipts occur, ongoing cash burn constrains the company’s ability to scale trials, absorb delays, or invest in broader commercial capabilities.
Ongoing Net Losses And Weak ProfitabilityDespite strong gross margins, Tango remains unprofitable at the EBIT and net levels. Sustained losses mean shareholder value hinges on successful clinical outcomes or partnerships; absent regulatory approvals and product revenue, profitability remains a structural risk for several years.
Revenue Dependent On Collaborations And MilestonesAs a clinical-stage biotech, Tango’s revenues are lumpy and milestone-driven, lacking recurring product sales. This makes cash flow timing unpredictable, increases reliance on external funding, and can cap upside from successful drugs if partnerships allocate a large share of future commercial economics to collaborators.
Tango Therapeutics News
TNGX FAQ
What was Tango Therapeutics’s price range in the past 12 months?
Tango Therapeutics lowest stock price was $1.03 and its highest was $13.48 in the past 12 months.
What is Tango Therapeutics’s market cap?
Tango Therapeutics’s market cap is $1.74B.
When is Tango Therapeutics’s upcoming earnings report date?
Tango Therapeutics’s upcoming earnings report date is Mar 30, 2026 which is in 40 days.
How were Tango Therapeutics’s earnings last quarter?
Tango Therapeutics released its earnings results on Nov 04, 2025. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of -$0.051 by $0.191.
Is Tango Therapeutics overvalued?
According to Wall Street analysts Tango Therapeutics’s price is currently Undervalued.
Does Tango Therapeutics pay dividends?
Tango Therapeutics does not currently pay dividends.
What is Tango Therapeutics’s EPS estimate?
Tango Therapeutics’s EPS estimate is -0.32.
How many shares outstanding does Tango Therapeutics have?
Tango Therapeutics has 134,677,100 shares outstanding.
What happened to Tango Therapeutics’s price movement after its last earnings report?
Tango Therapeutics reported an EPS of $0.14 in its last earnings report, beating expectations of -$0.051. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tango Therapeutics?
Currently, no hedge funds are holding shares in TNGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tango Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.67 (21.47% Upside)
$15.67 (21.47% Upside)
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $726.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.3%
Last 30 Days ▼ 8.7%
Last 30 Days ▼ 8.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
300.97%
12-Months-Change
Fundamentals
Return on Equity
-51.65%
Trailing 12-Months
Asset Growth
-40.37%
Trailing 12-Months
Company Description
Tango Therapeutics
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
TNGX Stock 12 Month Forecast
Average Price Target
$15.67
▲(21.47% Upside)
Technical Analysis
Oruka Therapeutics
―
Immatics
―
ARS Pharmaceuticals
―
Prime Medicine, Inc.
―
Upstream Bio, Inc.
―
Ownership Overview
Currently, No data available
---